Current disease status-First occurrence of the cancer Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

What are the effects of radical prostatectomy without pelvic lymph node dissection in prostate cancer?

Posted by on Nov 29, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of radical prostatectomy (RP) without pelvic lymph node dissection (PLND) in patients with prostate cancer. The main finding was that 5 years after treatment, 100% of patients at low risk for cancer recurrence had survived. Some background PLND is surgery to remove the lymph nodes from the pelvis....

Read More

Panitumumab improves the treatment outcomes of patients with advanced colorectal cancer

Posted by on Oct 27, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that this drug improved tumor response to the therapy. Some background CRC is one of the most common cancer worldwide. Chemotherapy such as FOLFOXIRI (leucovorin, fluorouracil, oxaliplatin,...

Read More

A later introduction of anti-EGFR drug is as effective as the standard therapy for advanced colorectal cancer

Posted by on Oct 27, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of chemotherapy combined with bevacizumab (Avastin) or anti-EGFR drugs for treating advanced colorectal cancer (CRC). Researchers suggested that anti-EGFR later introduced in the treatment of these patients did not impact the outcomes of patients.  Some background CRC is the third most common...

Read More

Comparing endocrine treatment versus chemotherapy for metastatic breast cancer

Posted by on Oct 22, 2019 in Breast cancer | 0 comments

In a nutshell This study compared hormone therapy and chemotherapy for the treatment of metastatic (cancer that has spread) breast cancer. The authors concluded that hormone therapy plus targeted therapy is better than chemotherapy for patients with metastatic breast cancer. Some background Different types of breast cancer have different receptors....

Read More

Evaluating long-term outcomes of nivolumab plus ipilimumab for patients with advanced melanoma

Posted by on Oct 20, 2019 in Melanoma | 0 comments

In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...

Read More

Surgery followed by chemotherapy improves the outcomes of patients with rectal cancer

Posted by on Oct 13, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of surgery followed by chemotherapy without chemoradiotherapy (CRT) before surgery to treat rectal cancer. Researchers suggested that this treatment improves the outcomes of these patients.  Some background Colorectal cancer is the third most common cancer worldwide. The standard...

Read More

Focal high-intensity focussed ultrasound for the treatment of localized prostate cancer

Posted by on Oct 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects.  Some background High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses...

Read More

Looking for patients with prostate cancer to test a combination of radiotherapy

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic ablative radiation therapy (SABR) and radiopharmaceutical therapy (RPT) in patients with oligometastatic (cancer spread in 1-2 other tissues or organs) prostate cancer. The main outcome will be progression-free survival (PFS). This trial is recruiting in Maryland,...

Read More

Evaluating long-term outcomes for stereotactic ablative body radiotherapy for early-stage non-small cell lung cancer.

Posted by on Aug 13, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using stereotactic ablative body radiotherapy (SABR) improves survival in patients with early-stage non-small cell lung cancer (NSCLC). The study found that this treatment resulted in good long-term survival and had few side effects. Some background Stereotactic ablative body radiotherapy (SABR) is...

Read More